Development of Amorphous Soft Magnetic Materials for Work at High Frequencies

В работе исследовались магнитомягкие аморфные сплавы системы (Fe1-xNix)79P5B12Si3C1 (x = 0; 0,2; 0,4; 0,5; 0,6). Были изучены магнитные свойства Hc, Ms, µe в исходном состоянии и после термической обработки при температуре (Tx–40) K для x = 0 и (Tg–20) K для x = 0,2–0,6 с продолжительностью выдержки от 0,6 до 3,6 кс.Soft magnetic amorphous alloys of the system (Fe1-xNix)79P5B12Si3C1(x = 0; 0,2; 0,4; 0,5; 0,6) were developed. The magnetic properties (Hc, Ms, µe) were studied in the initial state and after heat treatment at (Tx–40) K for x=0 and (Tg–20) K for x=0,2–0,6 for annealing times from 0.6 ks to 3.6 ks

Study of Amorphous Allos (Fe1-xNix)79P5B12Si3C1 System

In this work, magnetically soft amorphous alloys of the Fe–Ni–P–B–Si–C system. The crystallization kinetics of alloys has been investigated different thermal analysis by means of isothermal heating and continuous heating. As a result of isothermal annealing, Avrami exponents were found and mechanisms of crystallization were determined. Using continuous heating, the activation energy was found by the Kissinger method.В работе исследовались магнитомягкие аморфные сплавы системы Fe–Ni–P–B–Si–C. Была изучена кинетика кристаллизации сплавов с использованием термического анализа при режимах: изотермической выдержки и непрерывного нагрева. В результате проведения изотермического отжига были найдены показатели Аврами и определены механизмы кристаллизации. По методу Киссинджера при непрерывном нагреве определена энергия активация

Prevalence and risk factors for milk allergy overdiagnosis in the BEEP trial cohort.

BACKGROUND: Cow's milk allergy (CMA) overdiagnosis in young children appears to be increasing and has not been well characterised. We used a clinical trial population to characterise CMA overdiagnosis and identify individual-level and primary care practice-level risk factors. METHODS: We analysed data from 1394 children born in England in 2014-2016 (BEEP trial, ISRCTN21528841). Participants underwent formal CMA diagnosis at ≤2 years. CMA overdiagnosis was defined in three separate ways: parent-reported milk reaction; primary care record of milk hypersensitivity symptoms; and primary care record of low-allergy formula prescription. RESULTS: CMA was formally diagnosed in 19 (1.4%) participants. CMA overdiagnosis was common: 16.1% had parent-reported cow's milk hypersensitivity, 11.3% primary care recorded milk hypersensitivity and 8.7% had low-allergy formula prescription. Symptoms attributed to cow's milk hypersensitivity in participants without CMA were commonly gastrointestinal and reported from a median age of 49 days. Low-allergy formula prescriptions in participants without CMA lasted a median of 10 months (interquartile range 1, 16); the estimated volume consumed was a median of 272 litres (26, 448). Risk factors for CMA overdiagnosis were high practice-based low-allergy formula prescribing in the previous year and maternal report of antibiotic prescription during pregnancy. Exclusive formula feeding from birth was associated with increased low-allergy formula prescription. There was no evidence that practice prescribing of paediatric adrenaline auto-injectors or anti-reflux medications, or maternal features such as anxiety, age, parity and socioeconomic status were associated with CMA overdiagnosis. CONCLUSION: CMA overdiagnosis is common in early infancy. Risk factors include high primary care practice-based low-allergy formula prescribing and maternal report of antibiotic prescription during pregnancy

KD5170, a novel mercaptoketone-based histone deacetylase inhibitor that exhibits broad spectrum antitumor activity in vitro and in vivo

Abstract Histone deacetylase (HDAC) inhibitors have garnered significant attention as cancer drugs. These therapeutic agents have recently been clinically validated with the market approval of vorinostat (SAHA, Zolinza) for treatment of cutaneous T-cell lymphoma. Like vorinostat, most of the small-molecule HDAC inhibitors in clinical development are hydroxamic acids, whose inhibitory activity stems from their ability to coordinate the catalytic Zn 2+ in the active site of HDACs. We sought to identify novel, nonhydroxamate-based HDAC inhibitors with potentially distinct pharmaceutical properties via an ultra-high throughput small molecule biochemical screen against the HDAC activity in a HeLa cell nuclear extract. An A-mercaptoketone series was identified and chemically optimized. The lead compound, KD5170, exhibits HDAC inhibitory activity with an IC 50 of 0.045 Mmol/L in the screening biochemical assay and an EC 50 of 0.025 Mmol/L in HeLa cell -based assays that monitor histone H3 acetylation. KD5170 also exhibits broad spectrum classe

Gigliola Sulis speaks to Ann Goldstein: writing locally, translating globally

The conversation focuses on attitudes and trends in the US publishing market toward translated fiction. The strategies used by Goldstein as a translator of geo-centred and multilingual Italian novels are analysed, with reference to her translations of Pier Paolo Pasolini, Primo Levi, Elena Ferrante, Milena Agus, and Amara Lakhous

Dynamics and heterogeneity of Pb(II) binding by SiO 2 nanoparticles in an aqueous dispersion

ABSTRACT: Pb(II) binding by SiO2 nanoparticles in an aqueous dispersion was investigated under conditions where the concentrations of Pb2þ ions and nanoparticles are of similar magnitude. Conditional stability constants (log K) obtained at different values of pH and ionic strength varied from 4.4 at pH 5.5 and I = 0.1Mto 6.4 at pH 6.5 and I = 0.0015 M. In the range of metal to nanoparticle ratios from 1.6 to 0.3, log K strongly increases, which is shown to be due to heterogeneity in Pb(II) binding. For an ionic strength of 0.1 M the Pb2þ/SiO2 nanoparticle system is labile, whereas for lower ionic strengths there is loss of lability with increasing pH and decreasing ionic strength. Theoretical calculations on the basis of Eigen-type complex formation kinetics seem to support the loss of lability. This is related to the nanoparticulate nature of the system, where complexation rate constants become increasingly diffusion controlled. The ion binding heterogeneity and chemodynamics of oxidic nanoparticles clearly need further detailed research

Prevalence and risk factors for milk allergy overdiagnosis in the BEEP trial cohort

Background: Cow's milk allergy (CMA) overdiagnosis in young children appears to be increasing and has not been well characterised. We used a clinical trial population to characterise CMA overdiagnosis and identify individual‐level and primary care practice‐level risk factors. Methods: We analysed data from 1394 children born in England in 2014–2016 (BEEP trial, ISRCTN21528841). Participants underwent formal CMA diagnosis at ≤2 years. CMA overdiagnosis was defined in three separate ways: parent‐reported milk reaction; primary care record of milk hypersensitivity symptoms; and primary care record of low‐allergy formula prescription. Results: CMA was formally diagnosed in 19 (1.4%) participants. CMA overdiagnosis was common: 16.1% had parent‐reported cow's milk hypersensitivity, 11.3% primary care recorded milk hypersensitivity and 8.7% had low‐allergy formula prescription. Symptoms attributed to cow's milk hypersensitivity in participants without CMA were commonly gastrointestinal and reported from a median age of 49 days. Low‐allergy formula prescriptions in participants without CMA lasted a median of 10 months (interquartile range 1, 16); the estimated volume consumed was a median of 272 litres (26, 448). Risk factors for CMA overdiagnosis were high practice‐based low‐allergy formula prescribing in the previous year and maternal report of antibiotic prescription during pregnancy. Exclusive formula feeding from birth was associated with increased low‐allergy formula prescription. There was no evidence that practice prescribing of paediatric adrenaline auto‐injectors or anti‐reflux medications, or maternal features such as anxiety, age, parity and socioeconomic status were associated with CMA overdiagnosis. Conclusion: CMA overdiagnosis is common in early infancy. Risk factors include high primary care practice‐based low‐allergy formula prescribing and maternal report of antibiotic prescription during pregnancy